Lv31
260 积分 2025-04-07 加入
Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2
2小时前
已完结
RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches
29天前
已完结
Current developments in PI3K-based anticancer agents: Designing strategies, biological activity, selectivity, structure-activity correlation, and docking insight
29天前
已完结
Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects
29天前
已完结
Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents
29天前
已完结
Phenotypic Screening for Targeted Protein Degradation: Strategies, Challenges, and Emerging Opportunities
1个月前
已完结
HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2
1个月前
已完结
HER2-targeted therapies beyond breast cancer - an update
1个月前
已完结
HER2-Positive Breast Cancer Treatment and Resistance
1个月前
已完结
Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer
2个月前
已完结
皖公网安备34019202002308
